Data are provided by many contributors through the the WHO Clinical data platform and are not necessarily representative. To become a contributor, please see the terms of use and register here.

Total cases

76

Total facilities

2

Total PLWH

10

Women

35.5%

Children below 5

11.8%

Total deaths

0

The map below is just a proof of concept. Can be adjusted once/if we have data at the regional level.

Geospatial distribution
Cases reported
Mirror plots
Chronic conditions
Variable Sample size Prevalence pct Frequency
HIV (Human Immunodeficiency Virus) 76 13.2% 10 / 76
Hypertension 76 5.3% 4 / 76
Current new STI (Sexually Transmitted Infection) diagnosis? 76 2.6% 2 / 76
Syphilis 2 100.0% 2 / 2
Chronic heart disease 76 0.0% 0 / 76
Chronic lung disease 76 0.0% 0 / 76
Chronic kidney disease 76 0.0% 0 / 76
Chronic liver disease 76 0.0% 0 / 76
Chronic neurologic condition 76 0.0% 0 / 76
Current alcohol use disorder 76 0.0% 0 / 76
Previous COVID-19 infection 76 0.0% 0 / 76
Diabetes 76 0.0% 0 / 76
Currently smokes tobacco 76 0.0% 0 / 76
Skin Conditions 76 0.0% 0 / 76
Tuberculosis (previous) 76 0.0% 0 / 76
Tuberculosis (active) 76 0.0% 0 / 76
Asplenia 76 0.0% 0 / 76
Cancer 76 0.0% 0 / 76
Immunosuppressive condition 76 0.0% 0 / 76
N. gonorrhoeae 2 0.0% 0 / 2
HSV 2 0.0% 0 / 2
Chlamydia trachomatis 2 0.0% 0 / 2
HPV 2 0.0% 0 / 2
AIDS - defining illness 9 0.0% 0 / 9

Source: WHO
Complications
Variable Sample size Prevalence pct Frequency
Cellulitis 72 19.4% 14 / 72
Bacteraemia 72 11.1% 8 / 72
Abscess 72 5.6% 4 / 72
Anaemia 72 2.8% 2 / 72
Bacterial Pneumonia 72 2.8% 2 / 72
Ocular Complications 72 2.8% 2 / 72
Sepsis 72 1.4% 1 / 72
Urinary Retention 72 1.4% 1 / 72
Shock 72 0.0% 0 / 72
Seizure 72 0.0% 0 / 72
Encephalitis / Meningitis 72 0.0% 0 / 72
Bleeding Disorder 72 0.0% 0 / 72
Stroke / Cerebrovascular Accident 72 0.0% 0 / 72
Guillain-Barré Syndrome 72 0.0% 0 / 72
Cardiac Arrest 72 0.0% 0 / 72
Cardiac Arrhythmia 72 0.0% 0 / 72
Cardiomyopathy 72 0.0% 0 / 72
Myocarditis / Pericarditis 72 0.0% 0 / 72
Viral Pneumonia / Pneumonitis 72 0.0% 0 / 72
Acute Respiratory Distress Syndrome (Ards) 72 0.0% 0 / 72
Acute Renal Injury / Acute Renal Failure 72 0.0% 0 / 72
Pancreatitis 72 0.0% 0 / 72
Liver Dysfunction 72 0.0% 0 / 72
Necrotizing Infection 72 0.0% 0 / 72
Proctitis 72 0.0% 0 / 72
Rectal Urgency 72 0.0% 0 / 72
Rectal Pain 72 0.0% 0 / 72

Source: WHO
Body map of lesions at admission
Prevalence of lesions at admission
Variable Sample size Prevalence pct Frequency
Upper limb 75 82.7% 62/75
Chest and abdomen 75 80.0% 60/75
Head and neck 75 77.3% 58/75
Lower limb 75 73.3% 55/75
Back 75 72.0% 54/75
Genitals 75 48.0% 36/75
Mouth 74 27.0% 20/74

Source: WHO
Type of lesions
Variable Sample size Prevalence pct Frequency
Papule 76 76.3% 58/76
Macule 76 56.6% 43/76
Small pustule 76 38.2% 29/76
Umbilicated pustule 76 34.2% 26/76
Crusting of a mature lesion 76 32.9% 25/76
Early vesicle 76 28.9% 22/76
Ulcerated lesion 76 26.3% 20/76
Partially removed scab 76 18.4% 14/76

Source: WHO
Reported symptoms
Symptoms at admission
Variable Sample size Prevalence pct Frequency
Fever 75 84.0% 63 / 75
Headache 76 65.8% 50 / 76
Pruritis/itching 75 62.7% 47 / 75
Muscle pain or aching 76 59.2% 45 / 76
Fatigue or malaise 76 57.9% 44 / 76
Sore throat 76 40.8% 31 / 76
Joint pain or aching 76 30.3% 23 / 76
Pain in mouth 76 27.6% 21 / 76
Swallowing problem 76 27.6% 21 / 76
Painful swallow 21 95.2% 20 / 21
Urinary symptoms 76 22.4% 17 / 76
Pain with urination 17 100.0% 17 / 17
Psychologic disturbance 76 18.4% 14 / 76
Dizziness 76 13.2% 10 / 76
Nausea 76 7.9% 6 / 76
Difficult swallow 21 23.8% 5 / 21
Decrease urine output 16 25.0% 4 / 16
Ocular symptoms (pain, redness, visual loss) 76 3.9% 3 / 76
Vomiting 76 3.9% 3 / 76
Chest pain 76 3.9% 3 / 76
Red eye(s) 3 100.0% 3 / 3
Diarrhoea 76 2.6% 2 / 76
Any rectal symptom 76 2.6% 2 / 76
Urethral discharge 17 11.8% 2 / 17
Rectal pain 2 100.0% 2 / 2
Eye pain 3 33.3% 1 / 3
Other 3 33.3% 1 / 3
Proctitis 76 0.0% 0 / 76
Rectal discharge 2 0.0% 0 / 2
Rectal urgency/tenesmus 2 0.0% 0 / 2
Visual disturbance 3 0.0% 0 / 3
...with blood 3 0.0% 0 / 3

Source: WHO
Symptoms at discharge
Variable Sample size Prevalence pct Frequency
Sore throat 72 1.4% 1 / 72
Fever 71 0.0% 0 / 71
Pruritis/itching 70 0.0% 0 / 70
Muscle pain or aching 72 0.0% 0 / 72
Headache 72 0.0% 0 / 72
Ocular symptoms (pain, redness, visual loss) 72 0.0% 0 / 72
Fatigue or malaise 72 0.0% 0 / 72
Pain in mouth 72 0.0% 0 / 72
Nausea 72 0.0% 0 / 72
Vomiting 72 0.0% 0 / 72
Diarrhoea 72 0.0% 0 / 72
Any rectal symptom 72 0.0% 0 / 72
Swallowing problem 72 0.0% 0 / 72
Chest pain 72 0.0% 0 / 72
Joint pain or aching 72 0.0% 0 / 72
Proctitis 72 0.0% 0 / 72
Dizziness 72 0.0% 0 / 72
Psychologic disturbance 72 0.0% 0 / 72
Urinary symptoms 72 0.0% 0 / 72

Source: WHO
Variable

Person with HIV
N = 10

Person without HIV
N = 62

Unknown
N = 4

 p-value 1
age, Median (Q1, Q3) 11.00 (8.00, 12.00) 8.00 (5.00, 9.00) 9.50 (8.50, 10.00) 0.014
    Missing/Unknown 1 0 0
Sex at birth, n (%)


0.2
    Male 5 (50%) 40 (65%) 3 (75%)
    Female 4 (40%) 22 (35%) 1 (25%)
    Intersex 0 (0%) 0 (0%) 0 (0%)
    Unknown 1 (10%) 0 (0%) 0 (0%)
Race, n (%)


>0.9
    African/Black 9 (90%) 57 (92%) 4 (100%)
    Arab 0 (0%) 0 (0%) 0 (0%)
    Asian 0 (0%) 0 (0%) 0 (0%)
    Hispanic/Latino 0 (0%) 0 (0%) 0 (0%)
    Mixed Race 0 (0%) 0 (0%) 0 (0%)
    White 0 (0%) 0 (0%) 0 (0%)
    Unknown 1 (10%) 5 (8.1%) 0 (0%)
    Other 0 (0%) 0 (0%) 0 (0%)
health care worker, n (%)


0.3
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 9 (90%) 61 (98%) 4 (100%)
    Unknown 1 (10%) 1 (1.6%) 0 (0%)
Laboratory worker, n (%)


0.6
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 9 (90%) 59 (95%) 4 (100%)
    Unknown 1 (10%) 3 (4.8%) 0 (0%)
Sex worker, n (%)


0.025
    Yes 3 (30%) 2 (3.2%) 1 (25%)
    No 6 (60%) 56 (90%) 3 (75%)
    Unknown 1 (10%) 4 (6.5%) 0 (0%)
currently pregnant or was pregnant in the last 6 weeks?, n (%)


>0.9
    Yes 0 (0%) 1 (4.5%) 0 (0%)
    No 4 (100%) 21 (95%) 1 (100%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 6 40 3
Breastfeeding, n (%)



    Yes 0 (NA%) 0 (NA%) 0 (NA%)
    No 0 (NA%) 0 (NA%) 0 (NA%)
    Unknown 0 (NA%) 0 (NA%) 0 (NA%)
    Missing/Unknown 10 62 4
1

Kruskal-Wallis rank sum test; Fisher’s exact test
Variable

Person with HIV
N = 10

Person without HIV
N = 62

Unknown
N = 4

 p-value 1
ever hospitalized, n (%)


>0.9
    Yes 7 (88%) 49 (82%) 3 (100%)
    No 1 (13%) 11 (18%) 0 (0%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 2 2 1
Length of hospitalization, Median (Q1, Q3) 12 (5, 15) 6 (5, 12) 8 (6, 8) 0.3
    Missing/Unknown 3 13 1
Escalation of care, n (%)


0.2
    Yes 1 (14%) 0 (0%) 0 (0%)
    No 6 (86%) 49 (100%) 3 (100%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 3 13 1
supplemental oxygen, n (%)


0.2
    Yes 1 (14%) 0 (0%) 0 (0%)
    No 6 (86%) 49 (100%) 3 (100%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 3 13 1
receive nasogastric fluids, n (%)


>0.9
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 9 (100%) 60 (100%) 3 (100%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 1 2 1
receive IV fluids during course monkeypox infection, n (%)


0.037
    Yes 2 (22%) 2 (3.3%) 1 (33%)
    No 7 (78%) 58 (97%) 2 (67%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 1 2 1
receive analgesia for pain management, n (%)


0.013
    Yes 6 (67%) 20 (33%) 3 (100%)
    No 3 (33%) 40 (67%) 0 (0%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 1 2 1
receive antibiotics during course monkeypox infection, n (%)


0.4
    Yes 7 (78%) 55 (92%) 3 (100%)
    No 2 (22%) 5 (8.3%) 0 (0%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 1 2 1
receive antifungals during course monkeypox infection, n (%)


>0.9
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 9 (100%) 60 (100%) 3 (100%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 1 2 1
experimental antiviral during course monkeypox infection, n (%)


>0.9
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 8 (100%) 60 (100%) 3 (100%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 2 2 1
1

Fisher’s exact test; Kruskal-Wallis rank sum test
Variable

Person with HIV
N = 10

Person without HIV
N = 62

Unknown
N = 4

 p-value 1
History of tetanus vaccination, n (%)


0.3
    Yes 0 (0%) 6 (9.7%) 0 (0%)
    No 2 (20%) 21 (34%) 3 (75%)
    Unknown 8 (80%) 35 (56%) 1 (25%)
History of smallpox vaccination before 1980, n (%)


0.4
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 7 (70%) 52 (84%) 4 (100%)
    Unknown 3 (30%) 10 (16%) 0 (0%)
History of smallpox or monkeypox vaccination in past year, n (%)


0.6
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 9 (90%) 58 (94%) 4 (100%)
    Unknown 1 (10%) 4 (6.5%) 0 (0%)
Number of vaccines received, Median (Q1, Q3) NA (NA, NA) NA (NA, NA) NA (NA, NA)
    Missing/Unknown 10 62 4
1

Fisher’s exact test
Variable

Person with HIV
N = 10

Person without HIV
N = 62

Unknown
N = 4

 p-value 1
New diagnosis of HIV, n (%)


0.15
    Yes 0 (0%) 1 (1.7%) 0 (0%)
    No 7 (100%) 58 (97%) 2 (67%)
    Unknown 0 (0%) 1 (1.7%) 1 (33%)
    Missing/Unknown 3 2 1
Current new STI (Sexually Transmitted Infection) diagnosis, n (%)



    Yes 0 (0%) 0 (NA%) 0 (NA%)
    No 2 (100%) 0 (NA%) 0 (NA%)
    Unknown 0 (0%) 0 (NA%) 0 (NA%)
    Missing/Unknown 8 62 4
Immunosuppressive condition, n (%)


0.053
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 10 (100%) 62 (100%) 3 (75%)
    Unknown 0 (0%) 0 (0%) 1 (25%)
Most recent CD4, Median (Q1, Q3) 98 (98, 98) NA (NA, NA) NA (NA, NA)
    Missing/Unknown 1 62 4
Viral load, n (%)



    Detectable 0 (0%) 0 (NA%) 0 (NA%)
    Undetectable 3 (33%) 0 (NA%) 0 (NA%)
    Unknown 6 (67%) 0 (NA%) 0 (NA%)
    Missing/Unknown 1 62 4
AIDS - defining illness, n (%)



    Yes 0 (0%) 0 (NA%) 0 (NA%)
    No 9 (100%) 0 (NA%) 0 (NA%)
    Unknown 0 (0%) 0 (NA%) 0 (NA%)
    Missing/Unknown 1 62 4
1

Fisher’s exact test
Skin lesions by HIV status
Complications by HIV status
Exposure distribution
Variable Sample size Prevalence pct Frequency
Sexually active within ≤ 21 days prior to symptom onset? 76 44.7% 34/76
Number of heterosexual partners in the last three months 33 78.8% 26/33
Any known link to probable or confirmed case of monkeypox within ≤ 21 days prior to symptom onset? 76 9.2% 7/76
International travel within ≤ 21 days prior to symptom onset? 76 3.9% 3/76
Contact with possible animal source within ≤ 21 days prior to symptom onset? 76 0.0% 0/76
Did the patient receive experimental antiviral during course monkeypox infection? 71 0.0% 0/71

Source: WHO
Variable N = 76
Mpox clade known:, n (%)
    Yes 0 (0%)
    No 72 (100%)
    Unknown 0 (0%)
    Missing/Unknown 4
Mpox clade, n (%)
    Ia 0 (NA%)
    Ib 0 (NA%)
    IIa 0 (NA%)
    IIb 0 (NA%)
    Missing/Unknown 76
Monkeypox PCR, n (%)
    Yes 70 (97%)
    No 2 (2.8%)
    Unknown 0 (0%)
    Missing/Unknown 4
Monkeypox Result, n (%)
    Positive 34 (49%)
    Negative 34 (49%)
    Indeterminate 0 (0%)
    Unknown 2 (2.9%)
    Missing/Unknown 6
Monkeypox viral culture, n (%)
    Yes 0 (0%)
    No 72 (100%)
    Unknown 0 (0%)
    Missing/Unknown 4
Monkeypox viral culture Result, n (%)
    Positive 0 (NA%)
    Negative 0 (NA%)
    Indeterminate 0 (NA%)
    Unknown 0 (NA%)
    Missing/Unknown 76
Variable N = 76
Orthopoxvirus PCR, n (%)
    Yes 0 (0%)
    No 72 (100%)
    Unknown 0 (0%)
    Missing/Unknown 4
Orthopoxvirus Result, n (%)
    Positive 0 (NA%)
    Negative 0 (NA%)
    Indeterminate 0 (NA%)
    Unknown 0 (NA%)
    Missing/Unknown 76
Variable N = 76
Malaria result, n (%)
    Positive 0 (0%)
    Negative 3 (100%)
    Indeterminate 0 (0%)
    Unknown 0 (0%)
    Missing/Unknown 73
Syphilis result, n (%)
    Positive 1 (50%)
    Negative 1 (50%)
    Indeterminate 0 (0%)
    Unknown 0 (0%)
    Missing/Unknown 74
Variable

Baseline visit
N = 76
Hemoglobin, Median (Q1, Q3) 13.65 (11.20, 15.60)
WCC total, Median (Q1, Q3) 7.0 (6.3, 11.1)
Platelets, Median (Q1, Q3) 254 (158, 326)
PT, Median (Q1, Q3) NA (NA, NA)
APTT, Median (Q1, Q3) NA (NA, NA)
Total Bilirubin, Median (Q1, Q3) NA (NA, NA)
ALT, Median (Q1, Q3) NA (NA, NA)
AST, Median (Q1, Q3) NA (NA, NA)
Na+, Median (Q1, Q3) NA (NA, NA)
K+, Median (Q1, Q3) NA (NA, NA)
Urea/BUN, Median (Q1, Q3) NA (NA, NA)
Creatinine, Median (Q1, Q3) NA (NA, NA)
Glucose, Median (Q1, Q3) NA (NA, NA)
Lactate, Median (Q1, Q3) NA (NA, NA)
CRP, Median (Q1, Q3) NA (NA, NA)
Creatine kinase, Median (Q1, Q3) NA (NA, NA)
Variable

During infection management
N = 157
Hemoglobin, Median (Q1, Q3) 13.00 (11.40, 15.90)
WCC total, Median (Q1, Q3) 6.9 (5.1, 10.4)
Platelets, Median (Q1, Q3) 255 (159, 332)
PT, Median (Q1, Q3) NA (NA, NA)
APTT, Median (Q1, Q3) NA (NA, NA)
Total Bilirubin, Median (Q1, Q3) NA (NA, NA)
ALT, Median (Q1, Q3) NA (NA, NA)
AST, Median (Q1, Q3) NA (NA, NA)
Na+, Median (Q1, Q3) NA (NA, NA)
K+, Median (Q1, Q3) NA (NA, NA)
Urea/BUN, Median (Q1, Q3) NA (NA, NA)
Creatinine, Median (Q1, Q3) NA (NA, NA)
Glucose, Median (Q1, Q3) NA (NA, NA)
Lactate, Median (Q1, Q3) NA (NA, NA)
CRP, Median (Q1, Q3) NA (NA, NA)
Creatine kinase, Median (Q1, Q3) NA (NA, NA)
Variables Lab measures distribution
N Mean Median Min Max Distribution
Baseline visit
Hemoglobin 16.00 13.43 13.65 6.30 18.00
Platelets 16.00 277.00 253.50 93.00 731.00
WCC total 16.00 8.97 6.95 3.00 29.00
Outcomes